Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| INCYTE | 14 | 25 | -0,12 % | ||
| MODERNA | 9 | 16 | -0,54 % | ||
| GILEAD SCIENCES | 9 | 5 | +0,29 % | ||
| BIONTECH | 8 | 13 | +0,11 % | ||
| REGENXBIO | 7 | - | -2,68 % | ||
| MEDPACE | 6 | - | +0,77 % | ||
| EXELIXIS | 5 | 8 | +0,75 % | ||
| PERSONALIS | 4 | - | +0,90 % | ||
| REGENERON PHARMACEUTICALS | 2 | 22 | +0,25 % | ||
| SEPTERNA | 2 | 16 | +0,56 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:18 | Gilead outlines 6% HIV sales growth and $800M Yeztugo target for 2026 as launches accelerate | 4 | Seeking Alpha | ||
| 03:00 | Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch | 1 | Seeking Alpha | ||
| 00:42 | Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion | 3 | Investing.com | ||
| 00:18 | Gilead Sciences Q4 2025 slides: HIV growth drives solid results, robust pipeline ahead | 8 | Investing.com | ||
| 00:18 | FDA refuses to review Moderna's influenza vaccine application | 5 | Investing.com | ||
| 00:06 | Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance | 15 | Benzinga.com | ||
| 00:06 | Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma | 1 | GlobeNewswire (USA) | ||
| 00:02 | Moderna, Inc.: Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 | 534 | ACCESS Newswire | Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna has requested a Type A meeting to understand the path forwardmRNA-1010 has been... ► Artikel lesen | |
| Di | Gilead Sciences Inc. Q4 Profit Advances | 295 | AFX News | FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) released earnings for its fourth quarter that Increases, from the same period last yearThe company's bottom line totaled $2.183 billion, or... ► Artikel lesen | |
| Di | Gilead falls despite quarterly beats on disappointing 2026 EPS guidance | 8 | Seeking Alpha | ||
| Di | GALAPAGOS NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Di | Gilead in charts: Revenue from liver disease product sees highest Y/Y rise of 17% | 6 | Seeking Alpha | ||
| Di | Leerink Partners lowers Medpace stock price target on elevated cancellations | 2 | Investing.com | ||
| Di | Stifel initiates Olema Pharmaceuticals stock with Buy rating, $48 target | 1 | Investing.com | ||
| Di | Exelixis, Inc. Profit Climbs In Q4 | 12 | RTTNews | ||
| Di | Evommune Starts Making Case to Challenge Dominance of Sanofi's Dupixent in Atopic Dermatitis | 3 | MedCity News | ||
| Di | EXELIXIS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| Di | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 | 398 | PR Newswire | DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026... ► Artikel lesen | |
| Di | Earnings Snapshot: Gilead guides FY26 earnings below consensus after strong Q4 | 25 | Seeking Alpha | ||
| Di | Vaxcyte, Inc.: Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 | 2 | GlobeNewswire (USA) |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.